Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Alnylam from a "hold" to a "buy," joining several brokerages that rate the stock favorably.
• Q1 beat: Alnylam reported EPS of $1.99 vs. $0.90 expected and revenue of $1.17B (up 96% YoY), driven largely by a ~187% surge in Amvuttra sales.
• Despite positive results and a consensus "Moderate Buy" with a ~$471.96 price target, shares trade near $296 and insiders have sold stock recently, signaling mixed near‑term sentiment.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

ALNY has been the topic of several other research reports. Bank of America reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating on the stock in a research note on Thursday, February 12th. Barclays assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an "overweight" rating and a $527.00 target price on the stock. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating on the stock in a research note on Friday, January 30th. Finally, Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an "outperform" rating and a $500.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $471.96.

Alnylam Pharmaceuticals Trading Down 4.3%

Shares of ALNY opened at $296.11 on Friday. Alnylam Pharmaceuticals has a 52-week low of $245.96 and a 52-week high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The firm's fifty day moving average is $320.11 and its two-hundred day moving average is $377.45. The stock has a market cap of $39.51 billion, a PE ratio of 173.16 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 118.63%. The company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter in the previous year, the company posted ($0.44) EPS. The firm's quarterly revenue was up 96.4% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals will post 6.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president owned 59,802 shares in the company, valued at $18,543,404.16. The trade was a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total value of $677,530.36. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,058,797.44. This represents a 8.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 38,656 shares of company stock worth $12,370,696. Corporate insiders own 0.86% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $25,000. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. HM Payson & Co. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $27,000. Finally, Golden State Wealth Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 36 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.